Virax raises $3.25 million
Thursday, 13 January, 2005
Virax (ASX:VHL) has secured $3.25 million of the $4 million it was aiming to raise through a non-renounceable share purchase plan.
The funds will go towards the company's hepatitis B and prostate cancer programs. In late December 2004, Virax announced that a preclinical trial of a preliminary drug developed using its Co-X-Gene technology had induced an immune response against prostate cancer cells.
The company plans to commence animal toxicology work this year, with a view to moving into human trials.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
